Literature DB >> 9294820

Oxidation of human insulin-like growth factor I in formulation studies. 3. Factorial experiments of the effects of ferric ions, EDTA, and visible light on methionine oxidation and covalent aggregation in aqueous solution.

J R Fransson1.   

Abstract

The influence of ferric ions, EDTA, and visible light on the oxidation of methionine and the covalent reducible and nonreducible dimerization in human Insulin-like Growth Factor I (hIGF-I) in aqueous (1 mM) phosphate buffer solution were studied. A reduced factorial experiment with two levels of each factor was used. Regression models for the three responses were constructed with partial least square (PLS) analysis. The hIGF-I variants were quantified by reversed-phase high-performance liquid chromatography (RP-HPLC), gel filtration, and reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The formation of the hIGF-I variants in aqueous solution at pH 6.1 exhibited different dependencies on the variables studied. The oxidation of methionine was affected mainly by visible light and the combination of 10 ppm ferric ions and 20 ppm EDTA, whereas ferric ions alone had no significant effect. The covalent dimerization of hIGF-I was correlated to visible light and ferric ions. The interaction effects of ferric ions with either visible light or EDTA were also significant on the dimerization rates. Both reducible and nonreducible soluble covalent dimers were formed, with the reducible dimer being the most prominent. The oxidation of methionine 59 in hIGF-I is catalyzed by light and by ferric ions in combination with EDTA. The covalent dimerization of hIGF-I is mainly affected by light and by ferric ions. Both reducible and nonreducible dimerization increased by oxidative conditions. Human IGF-I appears to dimerize covalently by both disulfide scrambling and by a radical-promoted nondisulfide pathway. EDTA is necessary for ferric ions to be active in the oxidation of methionine in hIGF-I but not for the covalent dimerization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294820     DOI: 10.1021/js960484q

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  The biological activity of FasL in human and mouse lungs is determined by the structure of its stalk region.

Authors:  Raquel Herrero; Osamu Kajikawa; Gustavo Matute-Bello; Yi Wang; Naoki Hagimoto; Steve Mongovin; Venus Wong; David R Park; Nathan Brot; Jay W Heinecke; Henry Rosen; Richard B Goodman; Xiaoyun Fu; Thomas R Martin
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

2.  Mitigation of Oxidation in Therapeutic Antibody Formulations: a Biochemical Efficacy and Safety Evaluation of N-Acetyl-Tryptophan and L-Methionine.

Authors:  Michelle Z Dion; Danielle Leiske; Vikas K Sharma; Christina L Zuch de Zafra; Cleo M Salisbury
Journal:  Pharm Res       Date:  2018-10-02       Impact factor: 4.200

3.  Protein Formulations Containing Polysorbates: Are Metal Chelators Needed at All?

Authors:  Ema Valentina Brovč; Stane Pajk; Roman Šink; Janez Mravljak
Journal:  Antioxidants (Basel)       Date:  2020-05-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.